Latest Financial Results News

Liontown Resources reported robust FY25 results with over 294,000 dmt of spodumene concentrate produced and commenced underground mining on schedule. The company is transitioning to 100% underground production by Q3 FY26, aiming for scalable, low-cost operations from FY27 despite a 36% drop in spodumene prices.

Liontown Resources capped its first year at Kathleen Valley with over 300,000 tonnes of spodumene concentrate produced and a record $23 million in operating cash flow, despite a challenging lithium price environment. The company is on track to complete open pit mining by year-end and fully transition to underground operations by Q3 FY26.

Clime Investment Management has reported a solid operating profit for the June quarter, declared a fully franked dividend, and announced strategic expansions in staff and product offerings.

SomnoMed reports a robust Q4 FY25 with 25% revenue growth and a milestone of treating over 1 million patients, while gearing up for significant capacity expansion and clinical advancements.

Anatara Lifesciences reports Phase II GaRP-IBS trial results showing no safety concerns but missing the primary efficacy endpoint, while securing key patents and receiving a significant R&D tax refund.

Greatland Resources reports strong FY25 results with gold and copper production meeting guidance and costs significantly below expectations. The company advances Havieron feasibility and outlines ambitious FY26 growth capital plans to extend mine life and boost production.

EDU Holdings has reported record first-half FY25 results, propelled by strong enrolment growth at its Ikon Institute, while its vocational arm ALG faces headwinds from tighter student visa policies.

Aroa Biosurgery has reported its third consecutive quarter of positive net cash flow, maintaining a strong cash position and reaffirming its FY26 revenue and EBITDA guidance. The company’s Myriad product sales continue to grow, supported by new clinical evidence.

Spacetalk Ltd reports robust growth in paid mobile subscribers and recurring revenue for Q4 FY25, supported by strategic capital raises and international expansion.

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 amid promising regulatory and market developments.

Biome Australia Limited has delivered record sales revenue in Q4 FY25 alongside positive EBITDA, setting the stage for its first full-year net profit. Strategic product launches and international expansion underpin its strong growth trajectory.

Powerhouse Ventures Limited reports its first operating cash profit within a year of restructuring, driven by three distinct business divisions and a strengthened balance sheet.